Fas ligand expression in colon cancer: A possible mechanism of tumor immune privilege

World Journal of Gastroenterology

Volumn 11, Issue 23, 2005, Pages 3632-3635

  Zhang, Wei ^a   Ding, Er Xun ^a   Wang, Qiang ^a   Zhu, Da Qiao ^b   He, Jin ^a   Li, Yu Li ^a   Wang, Yuan He ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Colon cancer; Fas ligand; Immune privilege

Indexed keywords

FAS LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; COCULTURE; COLON ADENOMA; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LEUKEMIA CELL LINE; LIVER METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR IMMUNITY; UPREGULATION; WESTERN BLOTTING;

EID: 21344435974     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i23.3632     Document Type: Article

References (28)

1. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999; 20: 46-52
2. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med 1997; 3: 294-300
3. Redondo P, Solano T, VAzquez B, Bauza A, Idoate M. Fas and Fas ligand: expression and soluble circulating levels in cutaneous malignant melanoma. Br J Dermatol 2002; 147: 80-86
4. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57: 1007-1012
5. Ben-Hur H, Mordechay E, Halperin R, Gurevich P, Zandbank J, Herper M, Zusman I. Apoptosis-related proteins (Fas, Fas ligand, bcl-2 and p53) in different types of human breast tumors. Oncol Rep 2002; 9: 977-980
6. Mottolese M, Buglioni S, Bracalenti C, Cardarelli MA, Ciabocco L, Giannarelli D, Botti C, Natali PG, Concetti A, Venanzi FM. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer 2000; 89: 127-132
7. Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ, Mor G. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 2003; 63: 5573-5581
8. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995; 373: 441-444
9. Chen JJ, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998; 282: 1714-1717
10. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-1192
11. Arai H, Chan SY, Bishop DK, Nabel GJ. Inhibition of the alloantibody response by CD95 ligand. Nat Med 1997; 3: 843-848
12. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-632
13. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-1082
14. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack. Dis Esophagus 1999; 12: 83-89
15. O'Connell J, Bennett MW, O'Sullivan GC, Roche D, Kelly J, Collins JK, Shanahan F. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol 1998; 186: 240-246
16. Zhu Q, Deng C. The role of Fas/Fas ligand in tumorgenesis, immune escape, and counterattack in colonic cancer. Zhonghua Neike Zazhi 2002; 41: 378-380
17. Chen YL, Chen SH, Wang JY, Yang BC. Fas ligand on tumor cells mediates inactivation of neutrophils. J Immunol 2003; 171: 1183-1191
18. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160: 5669-5675
19. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR. Lymphocyte apoptosis induced by CD95(APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med 1996; 2: 1361-1366
20. Houston A, Bennett MW, O'Sullivan GC, Shanahan F, O'Connell J. Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression. Br J Cancer 2003; 89: 1345-1351
21. Yoong KF, Afford SC, Randhawa S, Hubscher SG, Adams DH. Fas/Fas ligand interaction in human colorectal hepatic metastases: a mechanism of hepatocyte destruction to facilitate local tumor invasion. Am J Pathol 1999; 154: 693-703
22. Lee SH, Kim HS, Kim SY, Lee YS, Park WS, Kim SH, Lee JY, Yoo NJ. Increased expression of FLIP, an inhibitor of Fas-mediated apoptosis, in stomach cancer. APMIS 2003; 111: 309-314
23. Baumler C, Duan F, Onel K, Rapaport B, Jhanwar S, Offit K, Elkon KB. Differential recruitment of caspase 8 to cFlip confers sensitivity or resistance to Fas-mediated apoptosis in a subset of familial lymphoma patients. Leuk Res 2003; 27: 841-851
24. Snow AL, Chen LJ, Nepomuceno RR, Krams SM, Esquivel CO, Martinez OM. Resistance to Fas-mediated apoptosis in EBV-infected B cell lymphomas is due to defects in the proximal Fas signaling pathway. J Immunol 2001; 167: 5404-5411
25. Mann B, Gratchev A, Böhm C, Hanski ML, Foss HD, Demel G, Trojanek B, Schmidt-Wolf I, Stein H, Riecken EO, Buhr HJ, Hanski C. FasL is more frequent expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 1999; 79: 1262-1269
26. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H. Expression of Fas ligand in liver metastases of human colon adenocarcinomas. Proc Natl Acad Sci USA 1997; 94: 6420-6425
27. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364
28. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 1990; 50: 6130-6138